These different outcomes throughout the literature can be explained because of (i) sample preparation with or without the addition of TSP as an HSA-binding competitor, (ii) inclusion of patients diagnosed with different stages of lung cancer, and (iii) patient-to-patient metabolic variability between groups. Here, ALB is linked to lung cancer.